CNS Pharmaceuticals, Inc. - Common Stock (CNSP)

New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find.

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline.

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets

South Korean scientists have published the results of a study that provides vital insights indicating that brain cancer develops much earlier than the time when tumors become visible. Their findings could alter how brain cancer treatment is approached, especially efforts geared at limiting the possibility of its recurrence.

Researchers at Keck Medicine, University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers.

Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics, and held senior leadership roles at Boston Scientific and Becton Dickinson. The Company said Dr. Kelley’s expertise in advancing clinical programs and executing regulatory strategy will support pipeline prioritization and long-term growth initiatives.

A new study may have just given brain surgeons a significantly better way to fight cancer without compromising how patients live afterward. Published in Science Advances, the research unlocks a layer of information already sitting in the operating room, one that surgeons have never had the tools to interpret until now.

Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS

The biomedical ecosystem in the U.S. is facing an unprecedented threat as younger researchers opt to work abroad amid the numerous challenges facing innovation within the United States. This brain drain particularly intensified starting last year when a number of policy changes left many with no option but to look for opportunities in other countries.

Brain tumors may damage surrounding tissue in a more insidious way than previously understood. New research from the University of Notre Dame shows that chronic pressure from an expanding tumor does not simply crush nearby neurons. It activates an internal self-destruction program that pushes those cells toward death.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers.

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation

A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered why some forms of breast cancer metastasize into the brain and become deadly. Their findings could open new doors in the management of breast cancer and address the needs of patients who are at a higher risk of developing metastases in the brain.

Mass General Brigham researchers have developed a new AI model that can estimate brain age, assess a patient’s risk of developing dementia, and help predict survival outcomes for brain cancer using routine MRI scans. The system, created within the Harvard-affiliated health network, is designed to pull multiple clinical signals from a single brain image rather than being trained for one narrow diagnostic task.

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery to remove a tumor has elicited excitement as it could provide a way forward in eliminating microscopic cancer tissue that surgeons are unable to see while surgically removing a cancerous tumor from the brain.

Scientists have designed a new class of nanoparticles that can actively remove harmful proteins from the body, a step that could reshape how some of the hardest diseases are treated. Instead of blocking problematic proteins, the approach focuses on eliminating them altogether.

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in the brains of mice. This has created hope that the compound could, in future, be made into a pill that can treat glioblastoma, one of the deadliest forms of brain cancer.

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation.

Researchers at the University of Michigan (U-M) have developed a system that leverages both AI and machine learning to create a digital twin of a patient’s brain cancer in order to predict how that patient will respond to different treatments. This tool promises to take personalized cancer care a step higher.

A new collaboration between Penn State College of Medicine and Targepeutics seeks to advance research into a promising combination therapy that offers hope to families with children diagnosed with DIPG (diffuse intrinsic pontine glioma).

University of North Carolina researchers have developed a combination treatment that shows remarkable promise against glioblastoma, an aggressive brain cancer with dismal survival rates. The therapy paired a standard chemotherapy drug with a laboratory chemical called EdU to produce unprecedented results in preclinical models.

The young population faces an increasing health challenge posed by brain tumors affecting adolescents and children. While their occurrence isn’t as common as that of other cancers in this demographic group, brain cancers account for the biggest fraction of fatalities related to cancer in this group. Many questions have therefore emerged regarding whether modern screens and lifestyles play a role in the rise of brain cancer among younger people.

Researchers have revealed a new blood test that can determine whether brain cancer therapies are being effective. The diagnostic tool could guide glioblastoma physicians on whether to maintain current drug regimens, change medications, or halt interventions altogether. Adam Sonabend, a Northwestern Medicine neurosurgeon who co-directed a study published in Nature Communications, explained that using this test, treatment effectiveness becomes apparent after a single dose instead of months of waiting.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under which John Climaco has stepped down as chief executive officer and Rami Levin, MBA, has been appointed president and chief executive officer, effective Jan. 1, 2026. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases, with a track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds, positioning CNS to advance its pipeline and next phase of development.